You are here

Article Text

Article menu
Download PDFPDF
Concise report
Intravenous immunoglobulins control scleromyxoedema
  1. A Righi1,
  2. F Schiavon2,
  3. S Jablonska3,
  4. A Doria2,
  5. M Blasczyk3,
  6. R Rondinone2,
  7. S Todesco2,
  8. M Matucci Cerinic1
  1. 1Department of Medicine, Division of Rheumatology, University of Florence, Italy
  2. 2Department of Medicine and Surgery, Division of Rheumatology, University of Padova, Italy
  3. 3Klinika Dermatogiczna, Warsaw, Poland
  1. Correspondence to:
    Professor M Matucci Cerinic, Department of Medicine, Division of Rheumatology, Villa Monna Tessa, Viale Pieraccini 18, 50139 Florence, Italy;
    cerinic{at}unifi.it

Abstract

Background: Scleromyxoedema is a variant of papular mucinosis affecting the skin and internal organs. The different therapeutic approaches proposed for scleromyxoedema are still unsatisfactory. Intravenous immunoglobulin (IVIg) has been successfully employed in the treatment of connective tissue diseases and vasculitides.

Patients: The successful treatment of three cases of scleromyxoedema with IVIg is reported here.

Conclusions: The relatively low risk of the drug and the high effectiveness seen in three patients suggest that IVIg is a new treatment potentially useful in scleromyxoedema.

  • intravenous immunoglobulins
  • scleromyxoedema
  • IL, interleukin
  • IVIg, intravenous immunoglobulin
  • TNF, tumour necrosis factor

https://doi.org/10.1136/ard.61.1.59

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes